MUSC/HCC Paul Calabresi Clinical Oncology Training Program Plan

MUSC/HCC Paul Calabresi 临床肿瘤学培训计划计划

• 批准号: 8486908
• 负责人: Andrew S Kraft
• 金额: $ 16.38万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2018-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8486908
• 关键词: Adult; Antineoplastic Agents; Applications Grants; Appointment; Area; Award; Basic Science; Biological; Cancer Center; Charge; Childhood; Clinic; Clinical; Clinical Oncology; Clinical Research; Clinical Sciences; Commit; Communities; Dental; Discipline of Nursing; Doctor of Pharmacy; Doctor of Philosophy; Ensure; Faculty; Funding; Funding Agency; Goals; Gynecologic Oncology; Laboratories; Laboratory Research; Malignant Neoplasms; Master of Science; Medical; Medicine; Mentored Clinical Scientist Development Program; Mentors; Monitor; National Cancer Institute; Neurologic; Operative Surgical Procedures; Otolaryngology; Participant; Pharmacy facility; Population Sciences; Postdoctoral Fellow; Prevention; Provider; Qualifying; Radiation; Recruitment Activity; Reporting; Research; Research Personnel; Resources; Rotation; SECTM1 gene; Schedule; Science; Scientist; Senior Scientist; Services; South Carolina; Time; Training; Training Programs; Translational Research; Translations; United States National Institutes of Health; Universities; Urology; Work; base; cancer care; cancer immunotherapy; cancer therapy; career development; clinical application; cohort; college; design; drug development; experience; insight; knowledge base; medical specialties; mortality; next generation; oncology; patient oriented; patient oriented research; programs

DESCRIPTION (provided by applicant): The Medical University of South Carolina's Hollings Cancer Center (MUSC/HCC) is committed to providing a physical and intellectual space to nurture tomorrow's leaders in clinical and translational oncology research. To accomplish this end, MUSC/HCC will establish the Paul Calabresi Clinical & Translational Oncology Training Program focused in three areas - cancer drug development, cancer immunotherapy, and cancer population sciences. The goal of this Program is to train successful, patient-oriented, clinical- and laboratory-based investigators who can work effectively in a collaborative, translational research setting. At the completion of the Program, these researchers will be able to independently design, implement and manage patient-oriented studies emphasizing both the translation of laboratory research findings into clinical applications, as well as laboratory studis examining the basic mechanisms of poorly understood clinical phenomena. Chosen participants, called Calabresi Scholars, will already hold a clinical or basic science qualifying professional degree. Clinically oriented Scholars will have recently completed postgraduate training in medical (adult or pediatric), radiation, surgical (including urology, otolaryngology, ad neurological subspecialties), or gynecologic oncology and will be ready for a first faculty appointment. Basic science Scholars will have a PhD or PharmD, will have completed at least two years of post-doctoral experience, and will be ready to develop a clinically-oriented, but laboratory-based, research program. To ensure the maturation of their knowledge base in clinical and translational research, each MUSC/HCC Calabresi Scholar will use the support from this K12 to develop a training plan within one of the three tracks in conjunction with an experienced mentoring team comprised of senior scientists (MDs and PhDs). Training will entail intensive course work (potentially leading to a Master of Science in Clinical Research) and an opportunity to participate in multiple, short-term laboratory and clinical research rotations durin the first quarter of the first year of training. This will be followed by a continuous, mentored, longitudinal laboratory and clinical research experience during the remainder of the first and second years of training. Each Scholar will be expected to complete three different but related milestones. Each Scholar will design and initiate a clinical cancer therapy trial (MD/DO Scholars) or a correlative science study (PhD/PharmD scholars), to answer a biological hypothesis-based clinical research question. As a second milestone, at least two publishable research reports should emanate from each of the Scholar's studies. Finally, the Scholar will be expected to create a fully developed grant application and submit it to a funding agency. An interdisciplinary Advisory Council will work closely with the Program Co-Directors in Year 01 to finalize all of the details of each training component and to have adequate time to recruit, externally and internally, for the best cohort of Scholars. Beginning in Year 02, the Program will appoint one or two Scholars annually, for a total of six Scholars. This MUSC/HCC Calabresi Training Program has been designed for a two year commitment. The Scholars will be selected by the Advisory Council, and the Advisory Council will also be charged to carefully monitor and evaluate each Scholar and the overall Program on a frequent and regular schedule. All Program components will utilize the considerable experience of scientists and mentors originating from MUSC's Colleges of Medicine, Pharmacy, Dental Medicine, Nursing and Graduate Medical Sciences, as well as the considerable research resources provided by the Hollings Cancer Center, a National Cancer Institute designated cancer center. The Program will also take full advantage of the career development services as part of MUSC's NIH funded Clinical and Translational Science Award. This K12 Program will provide the opportunity to maximize the HCC's potential in patient-oriented research while ensuring that the next generation of scientists is prepared to expedite the translation of science into the clinic and community. Another hallmark feature of this proposed K12 Program is that it is based in South Carolina, a state characterized by high cancer mortality, disparities and limited specialty providers, thus affording the Scholars with exceptional insight into the potential challenges of disseminating new standards of cancer care, prevention, and control emanating from the latest research.

描述（由申请人提供）：南卡罗来纳州医科大学的Hollings癌症中心（MUSC/HCC）致力于提供物理和智力空间，以培育明天的临床和翻译肿瘤学研究领导者。为了实现这一目标，MUSC/HCC将建立Paul Calabresi临床和转化肿瘤学培训计划，该计划集中在三个领域 - 癌症药物开发，癌症免疫疗法和癌症人群科学。该计划的目的是培训成功，以患者为导向的，临床和实验室的研究人员，他们可以在合作，转化研究环境中有效工作。该计划完成后，这些研究人员将能够独立设计，实施和管理以患者为导向的研究，强调了将实验室研究结果转化为临床应用的翻译，以及研究临床知识不足的基本机制的实验室研究。选定的名为Calabresi学者的参与者已经将拥有临床或基础科学资格专业学位。临床上导向的学者将最近完成医学（成人或儿科），辐射，手术（包括泌尿外科，耳鼻喉科学，AD神经学亚科）或妇科肿瘤学的研究生培训，并准备好接受第一次教师任命。基础科学学者将拥有博士学位或PharmD，将至少完成两年的博士后经验，并准备好开发以临床为导向但基于实验室的研究计划。为了确保其在临床和转化研究中的知识基础的成熟，每个MUSC/HCC Calabresi Scholar都会利用本k12的支持，与由高级科学家（MDS和PHDS）组成的经验丰富的指导团队一起在三个轨道之一中制定培训计划。培训将需要进行强化课程工作（有可能导致临床研究科学硕士），并有机会参加第一年培训第一年的第一季度，参加多个短期实验室和临床研究轮换。随后，在培训的第一年和第二年的剩余时间里，将是连续的，指导的，纵向的实验室和临床研究经验。每个学者都将完成三个不同但相关的里程碑。每个学者将设计并启动一项临床癌症治疗试验（MD/DO学者）或相关科学研究（PHD/PharmD学者），以回答基于生物学假设的临床研究问题。作为第二个里程碑，至少有两份可发布的研究报告应从学者的每个研究中散发出来。最后，学者将有望创建一个完全开发的赠款申请，并将其提交给资助机构。跨学科的咨询委员会将与计划的联合导演紧密合作，以最终确定每个培训部分的所有细节，并有足够的时间在外部和内部招募最好的学者。从02年开始，该计划将每年任命一两个学者，总共六个学者。该MUSC/HCC Calabresi培训计划已设计为两年的承诺。学者将由咨询委员会选出，咨询委员会还将收取经常和常规时间表的仔细监视和评估每个学者和整体计划。所有计划组成部分将利用来自MUSC医学，药房，牙科医学，护理和研究生医学科学学院的科学家和导师的丰富经验，以及由国家癌症研究所指定癌症中心的Hollings Cancer Center提供的大量研究资源。该计划还将充分利用职业发展服务作为MUSC资助的临床和转化科学奖的一部分。该K12计划将提供机会，以最大程度地发挥HCC在以患者为导向的研究中的潜力，同时确保下一代科学家准备将科学转化为诊所和社区。该提议的K12计划的另一个标志性特征是，它位于南卡罗来纳州，该州的特征是癌症死亡率高，差异和有限的专业提供者，因此提供 学者们对传播最新研究的癌症护理，预防和控制的新标准所面临的潜在挑战具有出色的洞察力。